| Patient Education |
|
Click here for patient education.
|
|
AUTHOR AND EDITOR INFORMATION
Section 1 of 10  
Author: Tsu-Yi Chuang, MD, MPH, Clinical Professor, Department of Dermatology, University of Southern California; Staff Dermatologist, Desert Specialty Group, Inc
Tsu-Yi Chuang is a member of the following medical societies: American Academy of Dermatology, American Society for Dermatologic Surgery, International Society for Dermatologic Surgery, and International Society of Dermatology
Coauthor(s):
Laura Stitle, MD, Staff Physician, Department of Dermatology, Indiana University Medical Center
Editors: David P Fivenson, MD, Associate Director, St Joseph Mercy Hospital Dermatology Program, Ann Arbor, Michigan; Michael J Wells, MD, Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center; Warren R Heymann, MD, Head, Division of Dermatology, Professor, Department of Internal Medicine, University of Medicine and Dentistry of New Jersey; Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania; Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Author and Editor Disclosure
Synonyms and related keywords:
LP, actinic lichen planus, annular lichen planus, atrophic lichen planus, erosive lichen planus, follicular lichen planus, guttate lichen planus, hypertrophic lichen planus, linear lichen planus, vesicular lichen planus, papular eruption, Wickham stria, hyperpigmentation, subungual hyperkeratosis, onycholysis, longitudinal melanonychia, atrophic cicatricial alopecia, pseudopelade, human leukocyte antigen B7, HLA-B7, human leukocyte antigen DR1, HLA-DR1, human leukocyte antigen DR10, HLA-DR10
Background
Lichen planus (LP) is a pruritic, papular eruption characterized by its violaceous color; polygonal shape; and, sometimes, fine scale. It is most commonly found on the flexor surfaces of the upper extremities, on the genitalia, and on the mucous membranes. LP is most likely an immunologically mediated reaction. See Oral Lichen Planus for more information on this variant of LP.
Pathophysiology
LP is a cell-mediated immune response of unknown origin. LP may be found with other diseases of altered immunity; these conditions include ulcerative colitis, alopecia areata, vitiligo, dermatomyositis, morphea, lichen sclerosis, and myasthenia gravis. An association is noted between LP and hepatitis C virus infection,1, 2, 3 chronic active hepatitis, and primary biliary cirrhosis.4 Hepatitis should be considered in patients with widespread or unusual presentations of LP. Onset or exacerbation of LP has been linked to stressful events.5
Frequency
United States
LP is reported in approximately 1% of all new patients seen at health care clinics. Some areas have reported a higher incidence in December and January.
International
No significant geographical variation in frequency exists.
Mortality/Morbidity
Atrophy and scarring are seen in hypertrophic lesions and lesions on the scalp. Cutaneous LP does not have a higher risk of skin cancer, but ulcerative lesions in the mouth, particularly in men, have a higher incidence of malignant transformation. However, in general, the malignant transformation rate of oral LP is low (<2% in one report). Vulvar lesions in women may also be associated with squamous cell carcinoma.
Race
No racial predispositions have been noted.
Sex
No significant differences in incidence are noted between male and female patients, but in women, LP may present as desquamative inflammatory vaginitis.6
Age
More than two thirds of patients are aged 30-60 years; however, LP can occur at any age.7
History
Most cases are insidious.
- The initial lesion is usually located on the flexor surface of the limbs, such as the wrists (see Media File 1). After a week or more, a generalized eruption develops with maximal spreading within 2-16 weeks.
- Pruritus is common but varies in severity depending on the type of lesion and the extent of involvement. Hypertrophic lesions are extremely pruritic.
- Oral lesions may be asymptomatic or have a burning sensation, or they may even be painful if erosions are present.
- In more than 50% of patients with cutaneous disease, the lesions resolve within 6 months, and 85% of cases subside within 18 months. On the other hand, oral LP had been reported to have a mean duration of 5 years. Large, annular, hypertrophic lesions and mucous membrane involvement are more likely to become chronic.
Physical
In addition to the cutaneous eruption, LP can involve the mucous membranes, the genitalia, the nails, and the scalp. The clinical presentation of LP has several forms: actinic, annular, atrophic, erosive, follicular, hypertrophic, linear, pigmented, and vesicular/bullous. The papules are violaceous, shiny, and polygonal; varying in size from 1 mm to greater than 1 cm in diameter (see Media File 2). They can be discrete or arranged in groups of lines or circles. Characteristic fine, white lines, called Wickham stria, are often found on the papules (see Media File 3). - Mucous membrane involvement is common and may be found without skin involvement. Lesions are most commonly found on the tongue and the buccal mucosa; they are characterized by white or gray streaks forming a linear or reticular pattern on a violaceous background (see Media File 4). Oral lesions are classified as reticular, plaquelike, atrophic, papular, erosive, and bullous. Ulcerated oral lesions may have a higher incidence of malignant transformation in men, but this observation may be confounded by other factors, such as smoking and chewing tobacco. Lesions may also be found on the conjunctivae, the larynx, the tonsils, the bladder, the vulva, and the vaginal vault; throughout the gastrointestinal tract; and around the anus.
- Genital involvement is common in men with cutaneous disease. Typically, an annular configuration of papules is seen on the glans. Less commonly, linear white striae, similar to the lesions on the vulva and the vagina, can be seen on male genitalia. Vulvar involvement can range from reticulate papules to severe erosions. Dyspareunia, a burning sensation, and pruritus are common. Vulvar and urethral stenosis can also be present. Two reports documented that more than 50% women with oral LP had undiagnosed vulvar LP.8, 9
- In 10% of patients, ungual findings are present. Most commonly, nail plate thinning causes longitudinal grooving and ridging. Hyperpigmentation, subungual hyperkeratosis, onycholysis, and longitudinal melanonychia can result from LP. Rarely, the matrix can be permanently destroyed with prominent pterygium formation. LP has been linked to childhood idiopathic nail atrophy and may overlap with twenty-nail dystrophy of childhood.
- Patients with a cutaneous eruption may also have follicular and perifollicular violaceous, scaly, pruritic papules on the scalp. These lesions can progress to atrophic cicatricial alopecia that can appear many weeks after the skin lesions have disappeared. Pseudopelade can be a final endpoint.
- Variations in LP include the following:
- Hypertrophic LP: These extremely pruritic lesions are most often found on the extensor surfaces of the lower extremities, especially around the ankles. Hypertrophic lesions are often chronic; residual pigmentation and scarring can occur when the lesions eventually clear.
- Atrophic LP: Atrophic LP is characterized by a few lesions, which are often the resolution of annular or hypertrophic lesions.
- Erosive LP: These lesions are found on the mucosal surfaces and evolve from sites of previous LP involvement.
- Follicular LP: Lichen planopilaris is characterized by keratotic papules that may coalesce into plaques. This condition is more common in women than in men, and ungual and erosive mucosal involvement is more likely to be present. A scarring alopecia may result.
- Annular LP: LP papules that are purely annular are rare. Annular lesions with an atrophic center can be found on the buccal mucosa and the male genitalia.
- Linear LP: Isolated linear lesions may form a zosteriform lesion, or they may develop as a Köbner effect.
- Vesicular and bullous LP: Most commonly, these lesions develop on the lower limbs or in the mouth from preexisting LP lesions. A rare condition, lichen planus pemphigoides, is a combination of both LP and bullous pemphigoid.
- Actinic LP: Subtropic or actinic LP occurs in regions, such as Africa, the Middle East, and India. This mildly pruritic eruption usually spares the nails, the scalp, the mucous membranes, and covered areas. Lesions are characterized by nummular patches with a hypopigmented zone surrounding a hyperpigmented center.
- LP pigmentosus: This is a rare variant of LP but can be more common in persons with darker-pigmented skin, such as Latinos or Asians. It usually appears on face and neck. Some believe it is similar to or the same as erythema dyschromicum perstans (ie, ashy dermatosis).
- LP pemphigoides: This is a rare form of LP. Blisters subsequently develop on LP lesions. Clinically, histopathologically and immunopathologically, it has features of LP and bullous pemphigoid, it but carries a better prognosis than pemphigoid.
Causes
The exact cause of LP is not known. The pathogenesis of LP is immunologically mediated. Whether the foreign antigen is a virus or a drug is not known. Langerhans cells process antigens, which are then presented to T lymphocytes. This stimulated lymphocytic infiltrate is epidermotropic and attacks keratinocytes. During this lymphocytotoxic process, the keratinocytes release cytokines that attract more lymphocytes. This process has been referred to as the lichenoid tissue reaction. In addition, recent studies reveal a disruption in the epithelial anchoring system.
Some patients with LP have a positive family history. It has been noted that affected families have an increased frequency of human leukocyte antigen B7 (HLA-B7). Others have found an association between idiopathic LP and human leukocyte antigen DR1 (HLA-DR1) and human leukocyte antigen DR10 (HLA-DR10); thus, LP may be influenced by a genetic predisposition.
Graft Versus Host Disease
Lichen Nitidus
Lichen Simplex Chronicus
Pityriasis Rosea
Psoriasis, Guttate
Psoriasis, Plaque
Syphilis
Tinea Corporis
Lab Studies
Direct immunofluorescence study reveals globular deposits of immunoglobulin M (IgM) and complement mixed with apoptotic keratinocytes.
Imaging Studies
No imaging studies are necessary.
Histologic Findings
The histopathologic features distinguish LP based on the presence of irregular acanthosis and colloid bodies in the epidermis with destruction of the basal layer. The upper dermis has a bandlike infiltrate of lymphocytes and histiocytes. The inflammatory reaction pattern is characteristic. The epidermis is hyperkeratotic with irregular acanthosis and focal thickening in the granular layer. Degenerative keratinocytes, known as colloid or Civatte bodies, are found in the lower epidermis. In addition to apoptotic keratinocytes, colloid bodies are composed of globular deposits of IgM (occasionally immunoglobulin G [IgG] or immunoglobulin A [IgA]) and complement. Linear or shaggy deposits of fibrin and fibrinogen are noted in the basement membrane zone. The upper dermis has a bandlike infiltrate of lymphocytic (primarily helper T) and histiocytic cells with many Langerhans cells. The infiltrate is very close to the epidermis and often disrupts the dermal-epidermal junction.
Medical Care
LP is a self-limited disease that usually resolves within 8-12 months. Mild cases can be treated with fluorinated topical steroids. More severe cases, especially those with scalp, nail, and mucous membrane involvement, may need more intensive therapy.
Consultations
Consult a dermatologist.
The first-line treatments of cutaneous LP are topical steroids, particularly class I or II ointments. A second choice would be systemic steroids for symptom control and possibly more rapid resolution. Many practitioners prefer intramuscular triamcinolone 40-80 mg every 6-8 weeks. Oral acitretin has been shown to be effective in published studies. Many other treatments are of uncertain efficacy because of the lack of randomized controlled trials. For LP of the oral mucosa, topical steroids are usually tried first. Topical and systemic cyclosporin have been tried with some success10; however, a randomized double-blind study indicated that topical cyclosporin was a less effective but much more costly regimen than clobetasol.11 Newer topical calcineurin inhibitors have replaced topical cyclosporin for the treatment of LP. Other options include oral or topical retinoids. Even with these effective treatments, relapses are common. Patients with widespread LP may respond to narrow-band or broadband UV-B therapy.12 Psoralen with UV-A (PUVA) therapy for 8 weeks has been reported to be effective. Risks and benefits of this treatment should be considered. PUVA is carcinogenic. Long-term risks include dose-related actinic degeneration, squamous cell carcinoma, and cataracts. A phototoxic reaction with erythema, pruritus, phytophotodermatitis, and friction blisters could occur. UV-A therapy combined with oral psoralen consists of oral psoralen (0.6 mg/kg), 1.5-2 hours before ultraviolet light, which usually starts at 0.5-1 J/cm2 and is increased by 0.5 J/cm2 per visit. Use of topical ointment at the time of receiving UV-A treatment may decrease the effectiveness of PUVA. Precaution should be taken for persons with a history of skin cancers or hepatic insufficiency.
Drug Category: Corticosteroids
These agents have anti-inflammatory properties and cause profound and varied metabolic effects. In addition, these agents modify the body's immune response to diverse stimuli. Topical steroids may be as effective as systemic steroids. Class I or II steroids in ointment form reduce pruritus in cutaneous LP, but they have not been proven to induce remission.
| Drug Name | Prednisone (Deltasone, Sterapred, Orasone) |
|---|
| Description | May decrease inflammation by reversing increased capillary permeability and suppressing PMN activity.
Use with extreme caution in children. Pediatric dose is determined more by severity of condition than by age or weight. |
|---|
| Adult Dose | 30-60 mg/d PO for 4-6 wk followed by gradual taper |
|---|
| Pediatric Dose | 4-5 mg/m2/d PO; alternatively, 0.05-2 mg/kg PO divided bid/qid; taper over 2 wk as symptoms resolve |
|---|
| Contraindications | Documented hypersensitivity; viral, fungal, tubercular skin, or connective tissue infections; peptic ulcer disease; hepatic dysfunction |
|---|
| Interactions | Coadministration with estrogens may decrease clearance; when used with digoxin, digitalis toxicity secondary to hypokalemia may increase; phenobarbital, phenytoin, and rifampin may increase the metabolism of glucocorticoids (consider increasing maintenance dose); monitor for hypokalemia with coadministration of diuretics; coadministration with ritonavir may significantly increase serum concentrations of prednisone; concomitant therapy with montelukast may result in severe peripheral edema; clarithromycin may increase risk of psychotic symptoms |
|---|
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
|
|---|
| Precautions | May unmask hypertension or diabetes or exacerbate peptic ulcer disease and tuberculosis; long-term sequelae associated with long-term steroid use include osteoporosis, cataracts, and pituitary-hypothalamic axis suppression; with high doses, patients may develop a steroid psychosis and are at increased risk of infections, particularly when oral steroids are used in conjunction with other immunosuppressants; frequently monitor patient's blood glucose level, blood pressure, and weight; monitor for Cushing syndrome; oral candidiasis may develop in patients treated for oral erosive LP |
|---|
| Drug Name | Betamethasone (Diprolene, Betatrex) |
|---|
| Description | For inflammatory dermatosis responsive to steroids. Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing capillary permeability. Use in pediatrics with extreme caution. Children have a larger skin surface area to body weight ratio and less developed, thinner skin, which may result in greater amounts of topical steroid being absorbed compared with adults. Use nonfluorinated topical corticosteroids. |
|---|
| Adult Dose | Oral LP: Apply gel to affected area q4-6h for 2-3 mo |
|---|
| Pediatric Dose | Apply as in adults |
|---|
| Contraindications | Documented hypersensitivity; paronychia; cellulitis; impetigo; angular cheilitis; erythrasma; erysipelas; rosacea; perioral dermatitis; acne |
|---|
| Interactions | None reported |
|---|
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
|---|
| Precautions | If treating large areas, systemic absorption may occur and produce reversible HPA-axis suppression with potential for glucocorticoid insufficiency after withdrawal of treatment; do not use in skin with decreased circulation; can cause atrophy of groin, face, and axillae; if infection develops and is not responsive to antibiotic treatment, discontinue until infection is under control |
|---|
| Drug Name | Triamcinolone (Aristocort) |
|---|
| Description | For inflammatory dermatosis responsive to steroids. Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing capillary permeability. Local injections have been reported to be effective. |
|---|
| Adult Dose | Hypertrophic lesions: 5 mg/mL (10 mg/mL formulation) injected into posterior nail fold q2-4wk for 3 treatments may improve ungual lesions; oral lesions can also be treated with intralesional injection of 5-10 mg/mL |
|---|
| Pediatric Dose | 2.5-15 mg (10 mg/mL or 40 mg/mL formulations intralesionally); repeat prn |
|---|
| Contraindications | Documented hypersensitivity; fungal, viral, and bacterial skin infections; hypertension; ocular herpes simplex (risk of corneal perforation); scleroderma; recent surgery; infection at treatment site |
|---|
| Interactions | None reported |
|---|
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
|---|
| Precautions | May cause skin atrophy and hypopigmentation; do not use in decreased skin circulation; prolonged use, applying over large areas, and using potent steroids and occlusive dressings may result in systemic absorption; systemic absorption may cause Cushing syndrome, reversible HPA-axis suppression, hyperglycemia, and glycosuria |
|---|
| Drug Name | Halobetasol (Ultravate) ointment, cream |
|---|
| Description | For inflammatory dermatosis responsive to steroids. Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing capillary permeability. Use in pediatrics with extreme caution. Children have a larger ratio of skin surface area to body weight and less developed, thinner skin, which may result in greater amounts of topical steroid being absorbed compared with adults. Use nonfluorinated topical corticosteroids. |
|---|
| Adult Dose | Apply to affected areas bid |
|---|
| Pediatric Dose | Not recommended |
|---|
| Contraindications | Documented hypersensitivity; paronychia; cellulitis; impetigo; angular cheilitis; erythrasma; erysipelas; rosacea; perioral dermatitis; acne |
|---|
| Interactions | None reported |
|---|
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
|---|
| Precautions | If treating large areas, systemic absorption may occur and produce reversible HPA-axis suppression with potential for glucocorticoid insufficiency after withdrawal of treatment; do not use in skin with decreased circulation; can cause atrophy of groin, face, and axillae; if infection develops and is not responsive to antibiotic treatment, discontinue until infection is under control |
|---|
Drug Category: Retinoids
These agents modulate cell proliferation.
| Drug Name | Isotretinoin (Accutane) |
|---|
| Description | Oral agent that treats serious dermatologic conditions. Synthetic 13-cis isomer of the naturally occurring tretinoin (trans-retinoic acid). Both agents are structurally related to vitamin A. Decreases sebaceous gland size and sebum production. May inhibit sebaceous gland differentiation and abnormal keratinization. |
|---|
| Adult Dose | 40 mg/d PO for several mo |
|---|
| Pediatric Dose | Not established |
|---|
| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Toxicity may occur with vitamin A coadministration; pseudotumor cerebri or papilledema may occur when coadministered with tetracyclines; may reduce plasma levels of carbamazepine
Increases toxicity of methotrexate (avoid concomitant use); interferes with effects of microdose progestin minipill; coadministration with alcohol may result in formation of etretinate, which has much longer half-life than acitretin (>120 d); may increase toxicity of phenytoin |
|---|
| Pregnancy | X - Contraindicated; benefit does not outweigh risk
|
|---|
| Precautions | May decrease night vision; inflammatory bowel disease may occur; may be associated with development of hepatitis and pancreatitis; diabetes patients may experience problems in controlling blood glucose while on isotretinoin; avoid exposure to UV light or sunlight until tolerance achieved; discontinue treatment if rectal bleeding, abdominal pain, or severe diarrhea occurs; mood swings or depression may occur; caution in history of depression |
|---|
| Drug Name | Tretinoin (Avita, Retin-A) |
|---|
| Description | May be effective for oral LP but not for cutaneous disease. Inhibits microcomedo formation and eliminates existing lesions. Makes keratinocytes in sebaceous follicles less adherent and easier to remove. Available as 0.025%, 0.05%, and 0.1% creams. Also available as 0.01% and 0.025% gels. |
|---|
| Adult Dose | Apply to affected area of mouth bid; begin with lowest tretinoin formulation and increase as tolerated; apply hs or qod; lower frequency of application if irritation develops |
|---|
| Pediatric Dose | <12 years: Not established
>12 years: Apply as in adults |
|---|
| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Other skin irritants (ie, astringents, benzoyl peroxide, salicylic acid, resorcinol, topical sulfur, other keratolytics, abrasives, astringents, spices, lime) may exacerbate irritation; coadministration with other drugs causing photosensitivity (eg, tetracycline, sulfonamides) may increase risk of sunburn |
|---|
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
|---|
| Precautions | Photosensitivity may occur with excessive sunlight exposure; burning, stinging, peeling, pruritus, or erythema has been reported at site of application; caution with eczema (may cause severe irritation); avoid contact with mucous membranes, mouth, and angles of nose |
|---|
| Drug Name | Acitretin (Soriatane) |
|---|
| Description | Retinoic acid analog, like etretinate and isotretinoin. Etretinate is main metabolite and has demonstrated clinical effects close to those seen with etretinate. Mechanism of action is unknown. |
|---|
| Adult Dose | 30 mg/d PO for 8 wk |
|---|
| Pediatric Dose | Not established |
|---|
| Contraindications | Documented hypersensitivity; pregnancy |
|---|
| Interactions | Increases toxicity of methotrexate (avoid concomitant use); interferes with effects of microdosed progestin minipill; coadministration with alcohol may enhance synthesis of etretinate, which has much longer half-life than acitretin (>120 d); topical drying or peeling agents; tetracyclines or photosensitizing medications |
|---|
| Pregnancy | X - Contraindicated; benefit does not outweigh risk
|
|---|
| Precautions | Most common adverse effects include cheilitis and dry mouth; hair loss, xerosis, hypertriglyceridemia, and impaired wound healing may occur; for women, a contraceptive period of 3 y after last intake of acitretin is recommended; do not use in severe obesity; women of childbearing age must be capable of complying with effective contraceptive measures; perform AST, ALT, and LDH tests prior to initiation of acitretin therapy at 1- to 2-wk intervals until stable and thereafter at intervals as clinically indicated |
|---|
Drug Category: Immunosuppressants
These agents modulate the immune system.
| Drug Name | Cyclosporine (Sandimmune, Neoral) |
|---|
| Description | Topical treatment under occlusion has been efficacious for genital lesions and may be beneficial in hypertrophic lesions. Mouthwash or oil-based solutions have been effective for oral LP but seem to be no better than corticosteroids. Systemic treatment has been used for severe resistant cutaneous disease, oral or ulcerative foot involvement, and lichen planopilaris of the scalp.
Pediatric population may require higher or more frequent dosing because of accelerated clearance; use with extreme caution. |
|---|
| Adult Dose | 1-2 mg/kg/d PO recommended starting dose; if no response, increase dose; usual dose is 5 mg/kg/d |
|---|
| Pediatric Dose | Administer as in adults |
|---|
| Contraindications | Documented hypersensitivity; uncontrolled hypertension or malignancies; do not administer concomitantly with PUVA or UV-B radiation in patients with psoriasis because it may increase risk of cancer |
|---|
| Interactions | Carbamazepine, phenytoin, isoniazid, rifampin, and phenobarbital may decrease concentrations; azithromycin, itraconazole, nicardipine, ketoconazole, fluconazole, erythromycin, verapamil, grapefruit juice, diltiazem, aminoglycosides, acyclovir, amphotericin B, and clarithromycin may increase toxicity; acute renal failure, rhabdomyolysis, myositis, and myalgias increase when taken concurrently with lovastatin |
|---|
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
|
|---|
| Precautions | Evaluate renal and liver functions often by measuring BUN, serum creatinine, serum bilirubin, and liver enzyme levels and blood pressure; may increase risk of infection and lymphoma; reserve IV use only for those who cannot take PO; adverse effects include nephrotoxicity, hypertension, hepatotoxicity, gingival enlargement, hyperkalemia, hypomagnesemia, pancreatitis, and paresthesia; factors that may increase risk for neurotoxicity from cyclosporine include hypomagnesemia, hypocholesterolemia, fever, infection, hypertension, intravenous administration, and rapidly increasing cyclosporine blood levels |
|---|
Complications
- Oral ulcerations have the potential to become malignant. Malignant transformation has been reported in ulcerative oral lesions in men.13
- Infection, osteoporosis, adrenal insufficiency, bone marrow suppression, renal damage, hyperlipidemia, and growth retardation in children may occur due to medication.
- Alopecia is often permanent.
- Hypertrophic lesions may leave residual hyperpigmentation.
- Vulvar lesions can be pruritic and painful.
Prognosis
- The prognosis for LP is good, as most cases regress within 18 months. Some cases recur.
Patient Education
- Patients should be told about the self-limiting nature of LP. Because LP is not common, no large, randomized, controlled clinical trials have been conducted for therapy. Several treatments may need to be tried.
- Patients should be told about the small likelihood of recurrence and the potential adverse effects from the various treatments offered.
| Media file 3:
Lichen planus shows Wickham striae (white, fine, reticular scales). |
 |  View Full Size Image | |
Media type: Photo
|
| Media file 4:
Lichen planus on the oral mucosa with ulceration in the center of the lesion appears with whitish papules and plaques in the periphery. |
 | View Full Size Image | |
Media type: Photo
|
- Chuang TY, Brashear R, Lewis C. Porphyria cutanea tarda and hepatitis C virus: a case-control study and meta-analysis of the literature. J Am Acad Dermatol. Jul 1999;41(1):31-6. [Medline].
- Chuang TY, Stitle L, Brashear R, Lewis C. Hepatitis C virus and lichen planus: A case-control study of 340 patients. J Am Acad Dermatol. Nov 1999;41(5 Pt 1):787-9. [Medline].
- Khaja MN, Madhavi C, Thippavazzula R, Nafeesa F, Habib AM, Habibullah CM, et al. High prevalence of hepatitis C virus infection and genotype distribution among general population, blood donors and risk groups. Infect Genet Evol. May 2006;6(3):198-204. [Medline].
- Korkij W, Chuang TY, Soltani K. Liver abnormalities in patients with lichen planus. A retrospective case-control study. J Am Acad Dermatol. Oct 1984;11(4 Pt 1):609-15. [Medline].
- Manolache L, Seceleanu-Petrescu D, Benea V. Lichen planus patients and stressful events. J Eur Acad Dermatol Venereol. Apr 2008;22(4):437-41. [Medline].
- Murphy R, Edwards L. Desquamative inflammatory vaginitis: what is it?. J Reprod Med. Feb 2008;53(2):124-8. [Medline].
- Balasubramaniam P, Ogboli M, Moss C. Lichen planus in children: review of 26 cases. Clin Exp Dermatol. Mar 18 2008;[Medline].
- Belfiore P, Di Fede O, Cabibi D, Campisi G, Amaru GS, De Cantis S, et al. Prevalence of vulval lichen planus in a cohort of women with oral lichen planus: an interdisciplinary study. Br J Dermatol. Nov 2006;155(5):994-8. [Medline].
- Di Fede O, Belfiore P, Cabibi D, De Cantis S, Maresi E, Kerr AR, et al. Unexpectedly high frequency of genital involvement in women with clinical and histological features of oral lichen planus. Acta Derm Venereol. 2006;86(5):433-8. [Medline].
- Lim KK, Su WP, Schroeter AL, Sabers CJ, Abraham RT, Pittelkow MR. Cyclosporine in the treatment of dermatologic disease: an update. Mayo Clin Proc. Dec 1996;71(12):1182-91. [Medline].
- Conrotto D, Carbone M, Carrozzo M, Arduino P, Broccoletti R, Pentenero M, et al. Ciclosporin vs. clobetasol in the topical management of atrophic and erosive oral lichen planus: a double-blind, randomized controlled trial. Br J Dermatol. Jan 2006;154(1):139-45. [Medline].
- Pavlotsky F, Nathansohn N, Kriger G, Shpiro D, Trau H. Ultraviolet-B treatment for cutaneous lichen planus: our experience with 50 patients. Photodermatol Photoimmunol Photomed. Apr 2008;24(2):83-6. [Medline].
- Gonzalez-Moles MA, Scully C, Gil-Montoya JA. Oral lichen planus: controversies surrounding malignant transformation. Oral Dis. May 2008;14(3):229-43. [Medline].
- [Medline].
- Boyd AS, Neldner KH. Lichen planus. J Am Acad Dermatol. Oct 1991;25(4):593-619. [Medline].
- Champion RH, ed. Rook/Wilkinson/Ebling Textbook of Dermatology. Vol 3. 6th ed. Malden, Mass: Blackwell Science; 1998:199-1916.
- Cribier B, Frances C, Chosidow O. Treatment of lichen planus. An evidence-based medicine analysis of efficacy. Arch Dermatol. Dec 1998;134(12):1521-30. [Medline].
- Fitzpatrick T, Eisen A, Wolff K, et al. Dermatology in General Medicine. Vol 1. 4th ed. New York, NY: McGraw-Hill; 1993:1134-44.
- Ingafou M, Leao JC, Porter SR, Scully C. Oral lichen planus: a retrospective study of 690 British patients. Oral Dis. Sep 2006;12(5):463-8. [Medline].
- Lewis FM. Vulval lichen planus. Br J Dermatol. Apr 1998;138(4):569-75. [Medline].
Lichen Planus excerpt Article Last Updated: Apr 18, 2008
|
